| 2026-03-14 |
详情>>
内部人交易：
McLeod Ian等共交易18笔
|
| 2026-03-03 |
详情>>
股本变动：
变动后总股本1340.08万股
|
| 2026-03-03 |
详情>>
业绩披露：
2025年年报每股收益-0.76美元,归母净利润-1088万美元,同比去年增长80.70%
|
| 2026-02-26 |
财报披露：
美东时间 2026-02-26 盘前发布财报
|
| 2025-11-05 |
详情>>
业绩披露：
2025年三季报(累计)每股收益-0.78美元,归母净利润-1117.2万美元,同比去年增长67.64%
|
| 2025-07-30 |
详情>>
业绩披露：
2025年中报每股收益-0.62美元,归母净利润-884.3万美元,同比去年增长-92.16%
|
| 2025-05-09 |
详情>>
业绩披露：
2025年一季报每股收益-0.34美元,归母净利润-487.3万美元,同比去年增长-7.95%
|
| 2025-04-28 |
股东大会：
将于2025-06-20召开股东大会
会议内容 ▼▲
- 1.Election of three Class II Directors;
2.Ratification of appointment of Deloitte & Touche LLP as Anika’s independent auditor for 2025;
3.Advisory “say-on-pay” vote on executive compensation;
4.Amendment of the Anika Therapeutics, Inc. 2017 Omnibus Incentive Plan.
|
| 2025-03-17 |
详情>>
业绩披露：
2022年年报每股收益-1.02美元,归母净利润-1485.9万美元,同比去年增长-459.43%
|
| 2025-03-17 |
详情>>
业绩披露：
2024年年报每股收益-3.83美元,归母净利润-5638.5万美元,同比去年增长31.79%
|
| 2024-11-04 |
详情>>
业绩披露：
2024年三季报(累计)每股收益-2.34美元,归母净利润-3452万美元,同比去年增长-75.52%
|
| 2024-08-08 |
详情>>
业绩披露：
2024年中报每股收益-0.31美元,归母净利润-460.2万美元,同比去年增长64.85%
|
| 2024-06-11 |
股东大会：
将于2024-07-09召开股东大会
会议内容 ▼▲
- 1.Election of three Class I Directors;
2.Ratification of appointment of Deloitte & Touche LLP as Anika’s independent auditor for 2024;
3.Advisory “say-on-pay” vote on executive compensation.
|
| 2024-05-08 |
详情>>
业绩披露：
2024年一季报每股收益-0.31美元,归母净利润-451.4万美元,同比去年增长56.39%
|
| 2024-03-15 |
详情>>
业绩披露：
2023年年报每股收益-5.64美元,归母净利润-8266.7万美元,同比去年增长-456.34%
|
| 2023-05-01 |
股东大会：
将于2023-06-14召开股东大会
会议内容 ▼▲
- 1.Election of three Class III Directors;
2.Ratification of appointment of Deloitte & Touche LLP as Anika’s independent auditor for 2023;
3.Advisory “say-on-pay” vote on executive compensation;
4.Advisory “say-on-frequency” vote on the frequency of future advisory votes on executive compensation;
5.Amendment of Anika Therapeutics, Inc. 2017 Omnibus Incentive Plan.
|
| 2022-04-27 |
股东大会：
将于2022-06-08召开股东大会
会议内容 ▼▲
- 1.Election of two Class II Directors;
2.Amendment of Anika Therapeutics, Inc. 2017 Omnibus Incentive Plan;
3.Ratification of appointment of Deloitte & Touche LLP as Anika’s independent auditor for 2022;
4.Advisory “say-on-pay” vote on executive compensation;
5.Any other matters that properly come before the Annual Meeting.
|
| 2022-03-10 |
复牌提示：
2022-03-09 09:30:36 停牌，复牌日期 2022-03-09 09:40:36
|
| 2021-09-06 |
温馨提示：
美股因劳工节，9月6日休市一天
|
| 2021-04-30 |
股东大会：
将于2021-06-16召开股东大会
会议内容 ▼▲
- 1.election of two Class I directors;
2.amendment of Anika Therapeutics, Inc. 2017 Omnibus Incentive Plan;
3.approval of Anika Therapeutics, Inc. 2021 Employee Stock Purchase Plan;
4.ratification of appointment of Deloitte & Touche LLP as Anika’s independent auditor for 2021;
5.advisory “say-on-pay” vote on executive compensation;
6.any other matters that properly come before the Annual Meeting.
|
| 2020-04-29 |
股东大会：
将于2020-06-16召开股东大会
会议内容 ▼▲
- 1.election of one Class III director;
2.amendment of the Anika Therapeutics, Inc. 2017 Omnibus Incentive Plan;
3.ratification of the appointment of Deloitte & Touche LLP as Anika’s independent auditor for 2020;
4.advisory “say on pay” vote on executive compensation;
5.any other matters that properly come before the Annual Meeting.
|
| 2019-04-25 |
股东大会：
将于2019-06-18召开股东大会
会议内容 ▼▲
- 1.election of three Class II directors;
2.amendment of the Anika Therapeutics, Inc. 2017 Omnibus Incentive Plan;
3.ratification of the appointment of Deloitte & Touche LLP as Anika’s independent auditor for 2019;
4.advisory “say on pay” vote on executive compensation;
5.any other matters that properly come before the Annual Meeting.
|
| 2018-04-17 |
股东大会：
将于2018-05-31召开股东大会
会议内容 ▼▲
- 1.election of two Class I directors;
2.reincorporation of Anika in Delaware;
3.increase in the number of authorized shares of common stock;
4.ratification of the appointment of Deloitte & Touche LLP as Anika’s independent registered public accounting firm for the year ending December 31, 2018;
5.advisory vote on executive compensation;
6.any other matters that properly come before the Annual Meeting.
|
| 2017-04-28 |
股东大会：
将于2017-06-13召开股东大会
会议内容 ▼▲
- 1.Election of two Class III directors;
2.Approval of the Anika Therapeutics, Inc. 2017 Omnibus Incentive Plan
3.Ratification of the appointment of Deloitte & Touche LLP as the Company’s independent registered public accounting firm for the 2017 fiscal year;
4.Advisory vote to approve executive compensation as disclosed in this proxy statement;
5.Advisory vote on the frequency of future advisory votes on executive compensation;
6.Any other matters that may properly come before the Annual Meeting.
|
| 2016-04-20 |
股东大会：
将于2016-06-01召开股东大会
会议内容 ▼▲
- 1.To elect two Class II directors, each to serve until the 2019 Annual Meeting of Stockholders and until their respective successors are duly elected and qualified;
2.To approve an amendment to the Company’s Restated Articles of Organization to increase the aggregate number of shares of common stock that the Company is authorized to issue to 120,000,000 shares from 30,000,000 shares;
3.To ratify the appointment of PricewaterhouseCoopers LLP as the Company’s independent registered public accounting firm for the 2016 fiscal year;
4.To consider and approve an advisory vote regarding the compensation of the Company’s Named Executive Officers;
5.To consider and act upon any other matters that may properly come before the Annual Meeting or any adjournment or postponement thereof.
|